BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33383383)

  • 21. Visualization and quantification of
    Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
    Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycyrrhizic acid facilitates anti-tumor immunity by attenuating Tregs and MDSCs: An immunotherapeutic approach.
    Juin SK; Ghosh S; Majumdar S
    Int Immunopharmacol; 2020 Nov; 88():106932. PubMed ID: 32890791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CCR5
    Blattner C; Fleming V; Weber R; Himmelhan B; Altevogt P; Gebhardt C; Schulze TJ; Razon H; Hawila E; Wildbaum G; Utikal J; Karin N; Umansky V
    Cancer Res; 2018 Jan; 78(1):157-167. PubMed ID: 29089297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
    Herrera-Rios D; Mughal SS; Teuber-Hanselmann S; Pierscianek D; Sucker A; Jansen P; Schimming T; Klode J; Reifenberger J; Felsberg J; Keyvani K; Brors B; Sure U; Reifenberger G; Schadendorf D; Helfrich I
    Front Immunol; 2020; 11():120. PubMed ID: 32117271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients.
    Petrova V; Groth C; Bitsch R; Arkhypov I; Simon SCS; Hetjens S; Müller V; Utikal J; Umansky V
    Front Immunol; 2023; 14():1065767. PubMed ID: 36860876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies.
    Hernandez C; Arasanz H; Chocarro L; Bocanegra A; Zuazo M; Fernandez-Hinojal G; Blanco E; Vera R; Escors D; Kochan G
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
    Kasanen H; Hernberg M; Mäkelä S; Brück O; Juteau S; Kohtamäki L; Ilander M; Mustjoki S; Kreutzman A
    Cancer Immunol Immunother; 2020 May; 69(5):717-730. PubMed ID: 32036449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
    Lin H; Wu Y; Chen J; Huang S; Wang Y
    Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma.
    Lau D; McLean MA; Priest AN; Gill AB; Scott F; Patterson I; Carmo B; Riemer F; Kaggie JD; Frary A; Milne D; Booth C; Lewis A; Sulikowski M; Brown L; Lapointe JM; Aloj L; Graves MJ; Brindle KM; Corrie PG; Gallagher FA
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34561275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positive Pelvic Lymph Nodes in Prostate Cancer Harbor Immune Suppressor Cells To Impair Tumor-reactive T Cells.
    Sharma V; Dong H; Kwon E; Karnes RJ
    Eur Urol Focus; 2018 Jan; 4(1):75-79. PubMed ID: 28753790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target.
    Ozbay Kurt FG; Lasser S; Arkhypov I; Utikal J; Umansky V
    J Clin Invest; 2023 Jul; 133(13):. PubMed ID: 37395271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
    Sevko A; Sade-Feldman M; Kanterman J; Michels T; Falk CS; Umansky L; Ramacher M; Kato M; Schadendorf D; Baniyash M; Umansky V
    J Invest Dermatol; 2013 Jun; 133(6):1610-9. PubMed ID: 23223128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice.
    Sevko A; Kremer V; Falk C; Umansky L; Shurin MR; Shurin GV; Umansky V
    J Immunotoxicol; 2012; 9(3):275-81. PubMed ID: 22449053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
    Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
    Front Immunol; 2020; 11():585214. PubMed ID: 33613512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
    Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloid-derived suppressor cells in malignant melanoma.
    Umansky V; Sevko A; Gebhardt C; Utikal J
    J Dtsch Dermatol Ges; 2014 Nov; 12(11):1021-7. PubMed ID: 25263083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
    Hernberg MM; Hahka-Kemppinen MH; Pyrhönen SO
    Melanoma Res; 2004 Dec; 14(6):493-500. PubMed ID: 15577320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of the functions of myeloid-derived suppressor cells : a new strategy of hydrogen sulfide anti-cancer effects.
    De Cicco P; Ercolano G; Rubino V; Terrazzano G; Ruggiero G; Cirino G; Ianaro A
    Br J Pharmacol; 2020 Feb; 177(4):884-897. PubMed ID: 31392723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of Progenitor Exhausted Tissue-Resident Memory CD8
    León-Letelier RA; Castro-Medina DI; Badillo-Godinez O; Tepale-Segura A; Huanosta-Murillo E; Aguilar-Flores C; De León-Rodríguez SG; Mantilla A; Fuentes-Pananá EM; López-Macías C; Bonifaz LC
    Front Immunol; 2020; 11():583382. PubMed ID: 33240271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.